Related Experiment Video

Updated: May 16, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Targeting VEGF signalling via the neuropilin co-receptor

Snezana Djordjevic1, Paul C Driscoll

  • 1Department of Structural and Molecular Biology, Institute of Structural and Molecular Biology, University College London, Gower Street, London WC1E 6BT, UK. s.djordjevic@ucl.ac.uk

Drug Discovery Today
|December 12, 2012
PubMed

Insights

Targeting tumor blood vessel growth (angiogenesis) is key in cancer drug development. New research reveals how co-receptors like neuropilins interact with vascular endothelial growth factor (VEGF) and its receptors, opening new therapeutic avenues.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Tumor vascularization and angiogenesis are critical targets in oncology.
  • Vascular Endothelial Growth Factor (VEGF) and its receptors (VEGFRs) have been historically targeted for anti-angiogenic therapies.
  • Neuropilin-1 (NRP1) and Neuropilin-2 (NRP2) act as co-receptors for specific VEGF isoforms, alongside VEGFRs, influencing VEGF-dependent signaling.

Purpose of the Study:

  • To review recent structural characterizations of VEGF interactions with NRP subdomains.
  • To discuss the impact of these structural insights on drug development for modulating VEGF signaling.

Main Methods:

  • Literature review of recent structural biology studies.
  • Analysis of research on VEGF, VEGFR, NRP1, and NRP2 interactions.
  • Examination of drug development strategies targeting these pathways.

Main Results:

  • Detailed structural insights into how VEGF isoforms bind to NRP subdomains in complex with VEGFRs.
  • Identification of specific interaction interfaces crucial for co-receptor function.
  • Emerging drug development strategies leveraging these structural findings.

Conclusions:

  • Understanding VEGF-NRP interactions provides new targets for anti-angiogenic therapies.
  • Structural characterization is accelerating the development of novel oncology drugs.
  • Targeting co-receptors offers a refined approach to inhibiting tumor angiogenesis.

More Related Videos

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina07:32

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Published on: June 23, 2014

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...